Genentech announces CHIMES trial results

Genentech, a member of Roche, announced results from the Phase IV CHIMES trial evaluating Ocrevus in Black and Hispanic / Latinx people with relapsing multiple sclerosis, or MS. One-year data from the trial show that Ocrevus effectively manages MS disease activity in these populations. Approximately half of all trial participants achieved no evidence of disease activity, or NEDA, at week 48, with over 94% of participants experiencing no relapses during this period. The safety and efficacy profile demonstrated in the trial was consistent with the large body of clinical evidence from other Ocrevus studies. The results were presented at the 9th Joint ECTRIMS-ACTRIMS Meeting in Milan. Additional results from the CHIMES trial showed more than 90% of trial participants had no 24-week confirmed disability progression and no T1-Gd+ lesions. During the trial period, no new or enlarging T2 lesions were observed in about half of Black participants and more than half of Hispanic / Latinx participants. No new safety signals were reported.